EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Lactylation in metabolic dysfunction-associated steatotic liver disease: epigenetic regulatory mechanisms and potential therapeutic strategies

Ya-Qi Guo, Dan-Jie Li, Chen-Xi Jia, Pan-Pan Hou, Chun-Jie Yang, Yu-Ting Xi, Xing Liu, Peng Li, Chang-Zheng Li, Qian-Qian Niu

Biochemical Pharmacology · 2026-09 · 251 · 118193

DOI: 10.1016/j.bcp.2026.118193 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2026-09. Verfasst von Ya-Qi Guo und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, North Henan Medical University, Xinxiang 453003, China. Electronic address: 20242082@sqmc.edu.cn. Hauptthemen laut MEDLINE: Epigenesis, Genetic, Fatty Liver, Lactic Acid, Non-alcoholic Fatty Liver Disease. Die Arbeit nennt 100 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic liver disease characterized by metabolic dysfunction as the central feature, and its onset and progression are closely associated with insulin resistance and energy metabolism reprogramming. Traditionally, lactate has been considered mainly as a metabolic byproduct generated during glycolysis. Recent studies, however, have indicated that lactate can also act as an important metabolic source for lysine lactylation modification, and it participates in the regulation of cellular metabolism. In the liver, lactylation can participate in the progression of MASLD by affecting multiple pathological processes, including lipid metabolism, inflammatory responses, and fibrosis. In addition, lactylation modification exhibits a dual regulatory role in MASLD, with both pro-pathological and protective effects. Intervention strategies targeting lactate metabolism and lactylation have gradually become an important direction in MASLD therapeutic research. This article systematically reviews the mechanisms of lactylation modification in MASLD as well as the research progress and translational limitations of related intervention strategies, aiming to provide a theoretical reference for the development of potential therapeutic targets for MASLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epigenesis, GeneticFatty LiverLactic AcidNon-alcoholic Fatty Liver DiseaseMetabolic DiseasesHumansAnimalsEnergy Metabolism

Stichwörter der Autor:innen

Bidirectional regulationEpigenetic modificationsLactylationMASLD

Substanzen

Lactic Acid

Autor:innen und Institutionen

  • College of Pharmacy, North Henan Medical University, Xinxiang 453003, China. Electronic address: 20242082@sqmc.edu.cn.
  • College of Pharmacy, Henan Medical University, Xinxiang 453003, China.
  • College of Pharmacy, North Henan Medical University, Xinxiang 453003, China.
  • Department of Hepatobiliary Surgery, Ganzi Branch of West China Hospital, Sichuan University, Ganzi 626700, China.
  • College of Pharmacy, North Henan Medical University, Xinxiang 453003, China. Electronic address: changzhengli@xxmu.edu.cn.
  • School of Basic Medical Sciences, Henan Medical University, Xinxiang 453003, China. Electronic address: niuqianqian1995@126.com.

Zitieren

APA

Guo, Y. Q., Li, D. J., Jia, C. X., Hou, P. P., Yang, C. J., Xi, Y. T., Liu, X., Li, P., Li, C. Z., & Niu, Q. Q. (2026). Lactylation in metabolic dysfunction-associated steatotic liver disease: epigenetic regulatory mechanisms and potential therapeutic strategies. Biochemical Pharmacology, 251, 118193. https://doi.org/10.1016/j.bcp.2026.118193

Vancouver

Guo YQ, Li DJ, Jia CX, Hou PP, Yang CJ, Xi YT, et al. Lactylation in metabolic dysfunction-associated steatotic liver disease: epigenetic regulatory mechanisms and potential therapeutic strategies. Biochemical Pharmacology. 2026;251:118193. doi:10.1016/j.bcp.2026.118193

BibTeX
@article{Guo2026,
  author = {Guo, Ya-Qi and Li, Dan-Jie and Jia, Chen-Xi and Hou, Pan-Pan and Yang, Chun-Jie and Xi, Yu-Ting and Liu, Xing and Li, Peng and Li, Chang-Zheng and Niu, Qian-Qian},
  title = {Lactylation in metabolic dysfunction-associated steatotic liver disease: epigenetic regulatory mechanisms and potential therapeutic strategies},
  journal = {Biochemical Pharmacology},
  year = {2026},
  volume = {251},
  pages = {118193},
  doi = {10.1016/j.bcp.2026.118193}
}
Kostenlos starten →